By Katherine Hamilton

ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer.

The stock climbed 32% to $7.94 on Wednesday. Shares have more than doubled over the past 12 months.

The immunotherapy company said Wednesday that the European Commission granted conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of adult patients with certain types of nonmuscle invasive bladder cancer.

With the authorization, Anktiva is now approved in 33 countries spanning four regulator jurisdictions. It was first approved by the U.S. Food and Drug Administration less than two years ago.

The authorization comes after patients treated with Anktiva demonstrated a 71% complete response rate in a recent clinical trial.

As part of the conditional authorization, ImmunityBio will follow up with trial participants and submit long-term safety and efficacy data to the European Medicines Agency, the company said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

February 18, 2026 14:00 ET (19:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.